Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Core Viewpoint - Merck (MRK) is expected to report quarterly earnings of $2.04 per share, an 18.6% increase year-over-year, with revenues projected at $16.19 billion, reflecting a 3.6% increase compared to the same period last year [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been revised downward by 85.2%, indicating a significant reassessment by analysts [2]. - Revisions to earnings estimates are crucial for predicting investor actions, as empirical research shows a strong correlation between earnings estimate trends and short-term stock performance [3]. Key Metrics Projections - Analysts estimate 'Sales- Vaccines- Vaxneuvance' at $178.52 million, a 10.9% increase year-over-year [5]. - 'Sales- Oncology- Keytruda' is projected to reach $8.31 billion, reflecting a 6.1% increase from the previous year [5]. - 'Sales- Oncology- Alliance revenue- Lenvima' is expected to be $243.71 million, indicating a 4.4% decrease year-over-year [5]. Additional Sales Estimates - 'Sales- Vaccines- Gardasil' is projected at $1.04 billion, showing a significant decline of 32.9% year-over-year [6]. - 'Sales- Hospital Acute Care- Bridion - U.S.' is expected to reach $418.39 million, a 9.5% increase year-over-year [6]. - 'Sales- Oncology- Keytruda - International' is estimated at $3.39 billion, reflecting a 13.3% increase year-over-year [6]. Further Sales Insights - 'Sales- Diabetes- Janumet - U.S.' is forecasted at $69.57 million, a decrease of 23.6% year-over-year [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - U.S.' is expected to be $176.62 million, showing a slight decrease of 0.2% [7]. - 'Sales- Oncology- Alliance revenue- Lynparza - International' is projected at $211.75 million, indicating a 13.2% increase year-over-year [8]. Market Performance - Merck shares have recorded a return of +1.6% over the past month, outperforming the Zacks S&P 500 composite's +0.8% change [9]. - Based on its Zacks Rank 4 (Sell), Merck is expected to underperform the overall market in the upcoming period [10].